Back to search
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) trials you may qualify forThis pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadel…
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acu…
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
This phase II trial tests the effect of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) with or without rituximab…
The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer c…
In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory…
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelph…
This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymph…